Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
CC transcript
AUXILIUM PHARMACEUTICALS INC (AUXL) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/29/2015 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "Amended and Restated Certificate of Incorporation of Auxilium Pharmaceuticals, Inc",
"Amended and Restated Bylaws of Auxilium Pharmaceuticals, Inc",
"Second Supplemental Indenture, among Auxilium Pharmaceuticals, Inc., Endo International plc and Wells Fargo Bank, National Association, as trustee"
01/27/2015 8-K Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AUXILIUM ANNOUNCES RESULTS FROM SPECIAL MEETING OF STOCKHOLDERS Chesterbrook, PA, January 27, 2015 — Auxilium Pharmaceuticals, Inc. , a specialty biopharmaceutical company, announced that it held a special meeting of its stockholders today at 8:30 a.m. ET to approve matters relating to the previously announced proposed merger with Endo International plc. The proposal to adopt the amended and restated agreement and plan of merger was passed by stockholders with approximately 84 percent of outstanding shares voting in favor. Auxilium anticipates that the proposed merger transaction will close on Thursday, January 29, 2015. “As we near the anticipated close of the transaction, I would like to take a moment to thank the Auxilium Board of Directors, the Executive Leadership Team and all of the ..."
01/20/2015 8-K Other Events
01/16/2015 8-K Other Events
12/22/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease Swedish Orphan Biovitrum AB and partner Auxilium Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the use of Xiapex® for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. The use of Xiapex in men with Peyronie's disease is supported by positive safety and efficacy outcome data from two double-blind placebo-controlled studies IMPRESS I and II . In December 2013, the United States Food and Drug Administration approved Xiaflex® for the treatment of adult men with Peyronie's disease with a palpable pl..."
12/19/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/16/2014 8-K Other Events
12/11/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Auxilium Announces Date for Special Meeting of Stockholders"
11/20/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AUXILIUM PHARMACEUTICALS, INC. PRESENTS STENDRA DATA AT SMSNA SCIENTIFIC MEETING"
11/20/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AUXILIUM PHARMACEUTICALS, INC. PRESENTS XIAFLEX FOR PEYRONIE'S DISEASE DATA AT SMSNA SCIENTIFIC MEETING"
11/19/2014 8-K Other Events
11/19/2014 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed Acquisition of Auxilium Pharmaceuticals"
11/17/2014 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
11/12/2014 8-K Entry into a Material Definitive Agreement
11/03/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AUXILIUM PHARMACEUTICALS, INC. TO PRESENT XIAFLEX AND STENDRA DATA AT SMSNA SCIENTIFIC MEETING"
10/30/2014 8-K Quarterly results
Docs: "AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2014 FINANCIAL RESULTS"
10/21/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES XIAFLEX NOW APPROVED FOR THE CONCURRENT TREATMENT OF UP TO TWO AFFECTED JOINTS IN THE SAME HAND IN DUPUYTREN'S CONTRACTURE PATIENTS"
10/09/2014 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Material Modifications to Rights ...
Docs: "Agreement and Plan of Merger, by and among Auxilium Pharmaceuticals, Inc., Endo International plc, Endo U.S. Inc., and Avalon Merger Sub Inc",
"Amendment No. 1 to Rights Agreement, by and between Auxilium Pharmaceuticals, Inc. and Broadridge Corporate Issuer Solutions, Inc",
"Termination Notice, from Auxilium Pharmaceuticals, Inc. to QLT Inc., QLT Holding Corp. and QLT Acquisition Corp",
"ENDO TO ACQUIRE AUXILIUM PHARMACEUTICALS IN A CASH AND STOCK TRANSACTION FOR APPROXIMATELY $2.6 BILLION"
09/22/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Incremental Assumption Agreement dated September 22, 2014, by and among Auxilium Pharmaceuticals, Inc., as borrower, and its existing domestic subsidiaries, as guarantors, the incremental term loan lenders from time to time party thereto and Morgan Stanley Senior Funding, Inc. as administrative agent, and as sole lead arranger and bookrunner"
09/22/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "AUXILIUM PROVIDES TRANSACTION UPDATE"
09/18/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AUXILIUM PHARMACEUTICALS, INC. PRESENTS XIAFLEX DATA FROM MULTICORD AND RETREATMENT STUDIES AT THE ASSH ANNUAL MEETING"
09/18/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Auxilium Pharmaceuticals, Inc. Keri P. Mattox Nichol L. Ochsner SVP, IR & Corporate Communications Senior Director, [email protected] IR & Corporate Communications 321-5900 [email protected] 321-5900 Eardley I, Montorsi F, Jackson G, et al Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int. 2007;100:122-129. American Urologic Association Treatment of ED Guidelines, http://emedicine.medscape.com/article/444220-overview, Accessed May 21, 2014."
09/17/2014 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Other Events, Financial Sta...
Docs: "Certificate of Designations of Series A Junior Participating Preferred Stock, as filed with the Secretary of State of the State of Delaware on September 17, 2014",
"Rights Agreement, between Auxilium Pharmaceuticals, Inc. and Broadridge Corporate Issuers Solutions, Inc., as Rights Agent",
"Endo 1400 Atwater Drive Malvern, PA 19355 Office: 484.216.4123 Email: [email protected] www.endo.com Rajiv De Silva President and Chief Executive Officer September 12, 2014 Adrian Adams Chief Executive Officer Auxilium Pharmaceuticals Inc. 640 Lee Road Chesterbrook, PA 19087"
09/10/2014 8-K Investor presentation
Docs: "Presentation materials to be first used by Adrian Adams, the Company's Chief Executive Officer and President, on September 10, 2014"
09/09/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES CORPORATE RESTRUCTURING DESIGNED TO STREAMLINE OPERATIONS, MAXIMIZE CASH FLOW AND DRIVE SUSTAINABLE EARNINGS GROWTH"
08/28/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AUXILIUM PHARMACEUTICALS, INC. TO PRESENT CCH DATA FOR CONCURRENT TREATMENT OF MULTIPLE DUPUYTREN'S CORDS AT ASSH ANNUAL MEETING"
08/21/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/21/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES POSITIVE DATA FROM PHASE 2A STUDY OF CCH IN PATIENTS WITH CELLULITE"
08/18/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Third Amendment Agreement to Credit Agreement dated August 14, 2014, by and among Auxilium Pharmaceuticals, Inc., as borrower, and its existing domestic subsidiaries, as guarantors, the certain lenders party thereto constituting Required Lenders under and as defined in the Credit Agreement and Morgan Stanley Senior Funding, Inc. as administrative agent, and as sole lead arranger and bookrunner"
08/11/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AUXILIUM PHARMACEUTICALS, INC. APPOINTS ANDREW SAIK CHIEF FINANCIAL OFFICER"
08/07/2014 8-K Quarterly results
Docs: "AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2014 FINANCIAL RESULTS"
08/05/2014 8-K Other Events
07/31/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AUXILIUM PHARMACEUTICALS, INC. ANNOUNCES XIAFLEX MILESTONE: PARTNER ASAHI KASEI PHARMA CORPORATION COMPLETES REGULATORY SUBMISSION FOR DUPUYTREN'S CONTRACTURE IN JAPAN"
06/26/2014 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Agreement and Plan of Merger, among Auxilium, QLT, HoldCo and AcquireCo",
"VOTING AGREEMENT",
"Auxilium Pharmaceuticals to Merge with Canadian Biotechnology Company QLT"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy